Clinical Trials Browser

Interventional × Sarcoma, Synovial × Dermatologic × Clear all

Melanoma, Sarcoma, Synovial

NCT02869217 2025-12-03

Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

DermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Urinary Bladder Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Synovial

NCT04483778 2025-11-20

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Phase 1 Active not recruiting

68 enrolled

CNSDermatologicGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Carcinoma, Melanoma, Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Hepatoblastoma, Sarcoma, Clear Cell, Neurofibrosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT05296564 2025-10-02

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Phase 1/2 Recruiting

3 enrolled

BreastCNSDermatologicGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Sarcoma, Synovial, Triple Negative Breast Neoplasms

NCT05492682 2025-09-05

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Phase 1 Active not recruiting

15 enrolled

BreastDermatologicGastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Sarcoma, Osteosarcoma, Sarcoma, Synovial, Colorectal Neoplasms, Liposarcoma, Myxoid, Triple Negative Breast Neoplasms

NCT03132922 2024-01-22

MAGE-A4ᶜ¹º³²T for Multi-Tumor

Phase 1 Active not recruiting

71 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT03399448 2023-06-22

NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

Phase 1 Terminated

3 enrolled

DermatologicPlasma cellSarcoma

Melanoma, Multiple Myeloma, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT03638206 2019-12-11

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Phase 1/2 Unknown

73 enrolled

CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

Burkitt Lymphoma, Carcinoma, Renal Cell, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Leukemia, Myeloid, Lung Neoplasms, Lymphoma, Melanoma, Mesothelioma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Sarcoma, Synovial, Colorectal Neoplasms

NCT02366546 2018-10-24

Investigator Initiated Phase 1 Study of TBI-1301

Phase 1 Unknown

9 enrolled

DermatologicGastrointestinalGynecologicHead & NeckSarcoma

Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Synovial

NCT00154388 2016-11-18

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Phase 2 Completed

185 enrolled

BreastDermatologicGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

Malignant mesenchymal tumor, Adenocarcinoma, Brenner Tumor, Carcinoma, Renal Cell, Chondrosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Hemangiopericytoma, Hemangiosarcoma, Leiomyosarcoma, Leukemia, Mast-Cell, Liposarcoma, Mastocytosis, Melanoma, Mesothelioma, Multiple Myeloma, Pleural Neoplasms, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Thymoma, Hypereosinophilic Syndrome, Sarcoma, Endometrial Stromal, Dermatofibrosarcoma, Rhabdomyosarcoma, Embryonal, Seminoma, Carcinoma, Ductal, Breast, Neurofibrosarcoma, Primary Myelofibrosis, Small Cell Lung Carcinoma

NCT02457650 2016-08-03

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies

Phase 1 Unknown

36 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Melanoma, Multiple Myeloma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Synovial

NCT00526149 2013-10-07

BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors

Phase 2 Completed

76 enrolled

BreastDermatologicGynecologicHead & NeckSarcoma

Malignant mesenchymal tumor, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fibrosarcoma, Head and Neck Neoplasms, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Melanoma, Ovarian Neoplasms, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Endometrial Neoplasms, Sarcoma, Endometrial Stromal, Sarcoma, Alveolar Soft Part, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous, Desmoplastic Small Round Cell Tumor

Clinical Trials

ACTengine® IMA203 Combined With mRNA-4203

Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

MAGE-A4ᶜ¹º³²T for Multi-Tumor

NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Investigator Initiated Phase 1 Study of TBI-1301

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies

BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors